Cytek Biosciences, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $201.5M | $200.5M | $193.0M | $164.0M | $128.0M |
| Cost of revenue | $97.0M | $89.3M | $83.6M | $63.1M | $48.8M |
| Gross profit | $104.5M | $111.1M | $109.4M | $101.0M | $79.1M |
| Research and development | $36.5M | $39.4M | $44.2M | $34.9M | $24.4M |
| Operating expenses | $144.8M | $131.6M | $137.3M | $102.8M | $70.0M |
| Operating income | -$40.4M | -$20.5M | -$27.8M | -$1.8M | $9.2M |
| Interest expense | $474,000 | $5.2M | $2.1M | $2.6M | $1.7M |
| Pretax income | -$29.8M | -$5.7M | -$15.7M | $1.3M | $5.9M |
| Income tax expense | $36.7M | $320,000 | -$3.6M | -$1.2M | $2.9M |
| Net income | -$66.5M | -$6.0M | -$12.1M | $2.5M | $3.0M |
| Balance Sheet | |||||
| Cash and equivalents | $90.9M | $98.7M | $167.3M | $296.6M | $364.6M |
| Current assets | $392.0M | $396.4M | $392.1M | $454.0M | $431.7M |
| Total assets | $461.5M | $499.5M | $494.5M | $519.5M | $463.3M |
| Current liabilities | $77.8M | $67.7M | $56.2M | $49.0M | $33.2M |
| Total liabilities | $119.8M | $103.8M | $101.4M | $93.9M | $57.9M |
| Total debt | $525,000 | $1.1M | $1.6M | $2.3M | $0 |
| Stockholders' equity | $341.7M | $395.7M | $393.1M | $425.5M | $405.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$4.7M | $25.4M | $5.3M | -$12.2M | $4.6M |
| Depreciation and amortization | $7.6M | $7.2M | $6.0M | $2.5M | $1.2M |
| Stock-based compensation | $24.6M | $26.8M | $22.0M | $16.6M | $6.6M |
| Capital expenditure | $4.1M | $3.5M | $4.6M | $9.7M | $4.4M |
| Free cash flow | -$8.8M | $21.9M | $633,000 | -$22.0M | $266,000 |
| Share repurchases | $15.1M | $21.6M | $44.2M | $0 | $0 |
Shares outstanding 129.1M · Free float 89.4%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.